Acalabrutinib

About

Therapy type: Targeted therapy

Therapy strategy: BTK inhibition

Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) TP53 somatic variants Chronic Lymphocytic Leukemia Acalabrutinib
HSE (1) TP53 deletion Chronic Lymphocytic Leukemia Acalabrutinib
HSE (1) 17p deletion Chronic Lymphocytic Leukemia Acalabrutinib